TrendingNews.today

S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|

S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|

As of Mar 27

HealthUnited States1 sourcesNeutral

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

TM

tristan manalac

via Biospace

March 27, 2026 | 12:00 AM UTCUpdated 1h ago

Share Read original

Read the full article at Biospace →

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Comments

0 comments

Be respectful and constructive.

Loading comments...

prediction, team news, lineups

Heres How A Simple Blood Test Could Potentially Detect Cancers Early

Related Articles

Hilltop Hoods’ Auction Raises $95,000 For Cancer Charity

Hilltop Hoods’ Auction Raises $95,000 For Cancer Charity

Hilltop Hoods,Lars Brandle-4h ago-1 sources

Jiuzhitang Co., Ltd. Announces Advance In Full Year Profit

Unknown-4h ago-1 sources

Gold Prices Rebound In Cautious Trade

Unknown-4h ago-2 sources

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency | TrendingNews.today